Back

Talem Health, LLC

  • Leukemia, Lymphocytic, Chronic, B-Cell

Navigating Resistance, Relapse, and Treatment Sequencing in Relapsed/Refractory CLL

After completing this activity, participants should be better able to: Evaluate clinical trial data on the efficacy and safety of current and emerging treatments for CLL in the relapsed/refractory setting Develop individualized treatment plans for patients with CLL based on the latest clinical evidence, guideline recommendations, and patient characteristics Integrate a multidisciplinary approach to improve treatment adherence, adverse event management, and coordinated care for patients with CLL in rural and underserved settings

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 0.5 credits
  • Commercial Support
  • Released
    Dec 19, 2025
  • Last day to claim credit
    Dec 20, 2026 2 months left